Mr Andurand is the founder and Chief Investment Officer of Andurand Capital and was previously founder and Chief Investment Officer at BlueGold, both global commodities hedge funds with peak assets of US$1.6bn and US$2.4bn under management, respectively. Mr Andurand’s previous career was as an energy trader at Vitol SA where he was Partner, before that at Bank of America and formerly at Goldman Sachs. He holds a Masters in International Finance from HEC, Paris and an Engineering Degree in Applied Mathematics from INSA, Toulouse, France.
Yen ChooExecutive Chairman
Dr Choo is Executive Chairman of Plasticell Ltd and Chief Executive of Progenitor Labs Ltd. He is the founder of Plasticell and served as Chief Executive and Chief Scientist of the company. Prior to his interest in stem cells he was a founder and Chief Scientist of Gendaq (acquired by Sangamo Biosciences), a biotech company that developed the zinc finger technology now used for gene editing. Previously he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge, where he pioneered the engineering of protein-DNA interactions using combinatorial methods under Nobel laureate Sir Aaron Klug. Dr Choo holds a PhD in Molecular Biology from the University of Cambridge and for his thesis received the Prize for Young Scientists awarded by GE Healthcare and Science (1996), and the Max Perutz Student Prize awarded by MRC-LMB (1995). He sits on the UK Stem Cell Steering Committee which oversees national stem cell research and the UK Stem Cell Bank .
Dr Ferris has more than 30 years experience in big pharma drug discovery and development, with a particular focus on the Japanese market. His early career was as a research chemist in Beecham Pharmaceuticals, UK, before being tasked to lead drug development at Beecham Yakuhin, Japan. Thereafter, at various times over the last 20 years, Dr Ferris held a number of senior executive and board positions in the Japanese subsidiaries of GSK, Aventis and Novartis. His latest position was President and representative Director, Novartis Holding K.K., supervising the various Novartis businesses operating in Japan. Dr Ferris holds a PhD in Chemistry from the University of Oxford and is a Fellow of the Royal Society of Chemistry.
Mr Saw is the Chief Executive of Plasticell Ltd and was formerly Chief Financial Officer of the company. Mr Saw gained a first class degree in the life sciences from Imperial College, London, and subsequently worked at the Max-Planck Institute, Berlin, in the human genome effort. He next founded his first business, before joining Goldman Sachs as an investment banker executing corporate finance solutions and mergers and acquisitions deals for clients in Europe and the US. Mr Saw is a serial entrepreneur, having also co-founded a capital markets consultancy firm, a merchant bank and a securities research & brokerage house. He has been working with Plasticell since 2009.